34 results
Thumbnail

D1.372 - Transition to SCIG as an Alternative in Patients with Cytokine Storm from IVIG

Thumbnail

D1.374 - Genetic susceptibility to radiocontrast media-induced anaphylaxis: A microarray gene chip study in a Korean population

Thumbnail

D1.365 - Long-term course of NSAID tolerance in patients with cross-hypersensitivity presenting with respiratory symptoms

Thumbnail

D1.366 - “Intense peri-vaginal itching as a lone symptom”: a unique presentation of Progesterone (Progestogen) hypersensitivity (PH)

Thumbnail

D1.367 - Risk factors for immediate hypersensitivity reactions to rituximab

Thumbnail

D1.369 - Immediate hypersensitivity to dostarlimab successfully managed with desensitization

Thumbnail

D1.370 - Desensitisation to low-dose acetylsalicylic acid in NERD. Clinical follow-up of aspirin therapy after desensitisation (ATAD)

Thumbnail

D1.371 - Nonsteroidal anti-inflammatory drug-induced acute urticaria/angioedema: antioxidant enzymes activities and associated genetic variants

Thumbnail

D1.373 - Hypersensitivity to Biologic Therapies: Mechanism of Cross-reactivity

Thumbnail

D1.375 - Retrospective Analysis of Perioperative Hypersensitivity Reactions: Single-Center Experience

Thumbnail

D1.376 - Successful Desensitization with Temozolomide in a Patient with a Hypersensitivity Reaction to Temozolomide

Thumbnail

D1.377 - Folic Acid Allergy: A Rare Case

Thumbnail

D1.378 - Hypersensitivity During Continuous 5-Fluorouracil Infusion: Two Cases Successfully Managed With Desensitization

Thumbnail

D3.440 - Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study

Thumbnail

D3.441 - Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study

Thumbnail

D3.444 - Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study

Thumbnail

D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial

Thumbnail

D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial

Thumbnail

D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial

Thumbnail

D3.439 - Donidalorsen For The Treatment Of Hereditary Angioedema: 1-Year Results From The OASISplus Open-Label Extension Cohort